第二代雄激素受体抑制剂在80岁及以上非转移性去势抵抗性前列腺癌患者中的生存结局:FDA三项随机试验患者水平汇总分析
该汇总分析纳入FDA截至2020年8月15日收到的三项随机试验,共4117例非转移性去势抵抗性前列腺癌患者,比较第二代雄激素受体抑制剂与安慰剂的疗效和安全性。
要点
- ≥80岁患者≥3级不良事件发生率55%,高于安慰剂组41%。
- ≥80岁患者最常见≥3级不良事件为高血压和骨折。
核心结论
- 汇总分析结果支持在老年非转移性去势抵抗性前列腺癌患者中使用第二代雄激素受体抑制剂。
- 在≥80岁患者中,雄激素受体抑制剂较安慰剂显著改善无转移生存和总生存,但≥3级不良事件更常见。
- 将老年综合评估工具纳入管理可能有助于为每例患者提供个体化治疗。
研究设计与样本
- 美国FDA汇总分析,检索截至2020年8月15日提交的二代雄激素受体抑制剂治疗非转移性去势抵抗性前列腺癌的随机对照试验,纳入三项符合标准的研究。
- 共4117例患者随机分配至雄激素受体抑制剂组(阿帕他胺、恩扎卢胺或达罗他胺,n=2694)或安慰剂组(n=1423)。
- 疗效分析在意向治疗人群中进行,按年龄(<80岁 vs ≥80岁)评估无转移生存和总生存;安全性分析纳入至少接受一剂研究治疗的患者。
- 无转移生存中位随访18个月(IQR 11-26),总生存中位随访44个月(32-55)。
主要发现
- ≥80岁患者中,≥3级不良事件在雄激素受体抑制剂组为371/672(55%),安慰剂组为140/344(41%);<80岁患者中分别为878/2015(44%)和321/1073(30%)。
关键数值与推荐
- ≥80岁患者中,雄激素受体抑制剂组最常见≥3-4级不良事件为高血压(51/672,8%)和骨折(36/672,5%);安慰剂组分别为22/344(6%)和11/344(3%)。
- <80岁患者中,雄激素受体抑制剂组高血压168/2015(8%)、骨折61/2015(3%);安慰剂组分别为53/1073(5%)和15/1073(1%)。
临床怎么用
- 对于≥80岁非转移性去势抵抗性前列腺癌患者,二代雄激素受体抑制剂可改善无转移生存和总生存,但需关注≥3级不良事件风险。
- 治疗决策时应结合老年综合评估工具,个体化权衡获益与安全性。
局限性
- 该分析为汇总分析,非预设的年龄亚组分析,年龄分层结果需谨慎解读。
- 随访时间有限,无转移生存中位随访仅18个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the benefit-risk profile of second-generation androgen receptor inhibitors in older men with non-metastatic castration-resistant prostate cancer. We aimed to examine the efficacy and safety of second-generation androgen receptor inhibitors in men aged 80 years or older with non-metastatic castration-resistant prostate cancer. METHODS: We searched for all randomised controlled clinical trials evaluating second-generation androgen receptor inhibitors in patients with non-metastatic castration-resistant prostate cancer submitted to the US Food and Drug Administration before Aug 15, 2020, and pooled data from three trials that met the selection criteria. All three trials enrolled patients who were aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-1, castration-resistant prostate cancer, prostate-specific antigen (PSA) 2·0 μg/L or greater, PSA doubling time of 10 months or less, and no evidence of distant metastatic disease on conventional imaging per the investigator's assessment at the time of screening. All patients had histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small-cell features. All patients who were randomly assigned to androgen receptor inhibitor or placebo groups in these trials were considered assessable and were included in this pooled analysis. We evaluated the effect of age on metastasis-free survival and overall survival across age groups (<80 years vs ≥80 years) in the intention-to-treat population. Safety analyses were done in patients who received at least one dose of study treatment. FINDINGS: Between Oct 14, 2013, and March 9, 2018, 4117 patients were assigned to androgen receptor inhibitor (apalutamide, enzalutamide, or daralutamide; n=2694) or placebo (n=1423) across three randomised trials. The median follow-up duration for metastasis-free survival was 18 months (IQR 11-26) and for overall survival was 44 months (32-55). In patients aged 80 years or older (n=1023), the estimated median metastasis-free survival was 40 months (95% CI 36-41) in the androgen receptor inhibitor groups and 22 months (18-29) in the placebo groups (adjusted hazard ratio [HR] 0·37 [95% CI 0·28-0·47]), and the median overall survival was 54 months (50-61) versus 49 months (43-58), respectively (adjusted HR 0·79 [0·64-0·98]). In patients younger than 80 years of age (n=3094), the estimated median metastasis-free survival was 41 months (95% CI 36-not estimable [NE]) in the androgen receptor inhibitor groups and 16 months (15-18) in the placebo groups (adjusted HR 0·31 [95% CI 0·27-0·35]), and the median overall survival was 74 months (74-NE) versus 61 months (56-NE), respectively (adjusted HR 0·69 [0·60-0·80]). In patients aged 80 years or older, grade 3 or worse adverse events were reported in 371 (55%) of 672 patients in the androgen receptor inhibitor groups and 140 (41%) of 344 patients in the placebo groups, compared with 878 (44%) of 2015 patients in the androgen receptor inhibitor groups and 321 (30%) of 1073 patients in the placebo groups among patients younger than 80 years. The most common grade 3-4 adverse events were hypertension (168 [8%] of 2015 patients aged <80 years and 51 [8%] of 672 patients aged ≥80 years in the androgen receptor inhibitor groups vs 53 [5%] of 1073 patients aged <80 years and 22 [6%] of 344 patients aged ≥80 years in the placebo groups) and fracture (61 [3%] and 36 [5%] in the androgen receptor inhibitor groups vs 15 [1%] and 11 [3%] in the placebo groups). INTERPRETATION: The findings of this pooled analysis support the use of androgen receptor inhibitors in older men with non-metastatic castration-resistant prostate cancer. Incorporating geriatric assessment tools in the care of older adults with non-metastatic castration-resistant prostate cancer might help clinicians to offer individualised treatment to each patient. FUNDING: None.
引用
- Fallah J, Zhang L, Amatya A, et al. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Lancet Oncol. 2021. PMID: 34310904. doi:10.1016/S1470-2045(21)00334-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。